Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.
Read original at benzingaStocks · News reference
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 11:15 AM
- Checked
- Jul 21, 2026, 11:15 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced new preclinical data demonstrating the
Read original at benzingaAkari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome modulating
Read original at benzingaAkari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Akari Therapeutics announced a strategic research collaboration with WhiteHawk Therapeutics to combine Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform for a novel dual-payload strategy. The company is advancing its lead candidate AKTX-101 toward Phase 1 clinical evaluation by mid-2027 and emphasizes that collaborations will play an increasingly important role in advancing next-generation ADC innovation.
Read original at globenewswire-inc